Latikafusp

Modify Date: 2025-08-24 08:53:36

Latikafusp structure	Common Name	Latikafusp
	CAS Number	2552814-07-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Latikafusp

Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research[1][2].

Name	Latikafusp

Description	Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
References	[1]. Greg Durm, et al. Abstract CT205: Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. [2]. Gregory Durm, et al. 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 2020, 8(Suppl 3).

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

References

[1]. Greg Durm, et al. Abstract CT205: Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301.

[2]. Gregory Durm, et al. 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 2020, 8(Suppl 3).

No Any Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Latikafusp

Use of Latikafusp

Names

Latikafusp Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.